FDA Alerts

The FDA has approved the first and only cancer immunotherapy for the initial treatment of certain bladder cancers.

The FDA has approved the first and only option for the treatment of all forms of diabetic retinopathy.

The US Food and Drug Administration has approved a new capsule for the treatment of the neurological disorder tardive dyskinesia.

The FDA has approved 2 new treatment options for children aged 12 to 17 with hepatitis C infection.

The US Food and Drug Administration has approved Austedo (deutetrabenazine) tablets for the treatment of chorea in patients with Huntington disease.

The FDA converted Ibrance to regular FDA approval and approved a supplemental New Drug Application for the drug, broadening its range of antihormonal therapy.

The FDA approved osimertinib for the treatment of patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer.

The FDA approved Ocrevus for the treatment of relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adult patients.

The US Food and Drug Administration has approved Dupixent for the treatment of moderate-to-severe eczema in adults.